NFL: Reports: WFT trainer Ryan Vermillion subject of prescription drug probe

Date:

Share post:


Washington Football Team head trainer Ryan Vermillion is being investigated for illegally distributing prescription drugs, the Washington Post and ESPN reported Thursday.

Federal law enforcement conducted a raid at the team’s practice facility and Vermillion’s home last week. On Monday, Washington placed him on administrative leave, saying in a statement it was “due to an ongoing criminal investigation that is unrelated to the team.”

Vermillion is not a physician, so by law he would not be allowed to disburse prescription drugs.

Earlier Thursday, the NFLPA informed agents that it has begun its own investigation into the matter.

“The work office and home of Ryan Vermillion were raided by the Drug Enforcement Agency, and one of our players has been contacted by federal investigators,” the memo revealed.

According to the initial report from NBC Sports Washington, the investigation into Vermillion has been ongoing for months.

Vermillion is in his second season with Washington after 18 seasons with the Carolina Panthers. He spent nine seasons with Washington coach Ron Rivera in Carolina when Rivera was coach of the Panthers from 2011-19.

–Field Level Media

spot_img

Related articles

NFL: Reports: Chiefs reach deal with rugby player

The Kansas City Chiefs agreed to terms with former rugby star Louis Rees-Zammit, multiple media outlets reported. Bleacher...

NFL: RB J.K. Dobbins to visit Chargers

Free-agent running back J.K. Dobbins is scheduled to visit the Los Angeles Chargers on Thursday, his agency confirmed...

NFL: Panthers sign Pro Bowl OLB Jadeveon Clowney

The Carolina Panthers flew under the radar and signed free agent outside linebacker Jadeveon Clowney on Wednesday. The team...

NFL: Report: Texans to sign LB Neville Hewitt

Free-agent linebacker Neville Hewitt is signing a one-year contract to rejoin the Houston Texans, ESPN reported on Wednesday. Financial...

FREE

Get the most important breaking news and analyses for Free.

Thank you for subscribing

Something went wrong.